These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

957 related items for PubMed ID: 19760546

  • 1. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN, Ratjen F.
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [Abstract] [Full Text] [Related]

  • 2. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Ratjen F.
    Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
    [Abstract] [Full Text] [Related]

  • 3. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P, Whitaker P, Peckham D.
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [Abstract] [Full Text] [Related]

  • 4. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA, Lory S, Brodie EL, Lynch SV, Bohannan BJ, Green JL, Maurer BA, Kolter R.
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [Abstract] [Full Text] [Related]

  • 5. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O.
    APMIS Suppl; 2003 May; (116):1-47. PubMed ID: 14692154
    [Abstract] [Full Text] [Related]

  • 6. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T.
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [Abstract] [Full Text] [Related]

  • 7. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D, Stableforth D.
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [Abstract] [Full Text] [Related]

  • 8. Antibiotic use in cystic fibrosis.
    Eisenberg JD.
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [Abstract] [Full Text] [Related]

  • 9. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR, Pressler T, Høiby N.
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [Abstract] [Full Text] [Related]

  • 10. [Cystic fibrosis and pseudomonas aeruginosa current and future strategies].
    Leonard A, Leal T, Lebecque P.
    J Pharm Belg; 2007 Nov; 62(1):25-8. PubMed ID: 17508664
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M, Smyth A, Geller DE.
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [Abstract] [Full Text] [Related]

  • 12. Eradication of early Pseudomonas aeruginosa infection.
    Høiby N, Frederiksen B, Pressler T.
    J Cyst Fibros; 2005 Aug; 4 Suppl 2():49-54. PubMed ID: 16023416
    [Abstract] [Full Text] [Related]

  • 13. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD, Elborn JS.
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [Abstract] [Full Text] [Related]

  • 14. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS.
    APMIS Suppl; 1992 Oct; 28():1-79. PubMed ID: 1449848
    [Abstract] [Full Text] [Related]

  • 15. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum BN, Meyer P, Pressler T, Lindblad A, Scandinavian CF Study Consortium (SCFSC).
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [Abstract] [Full Text] [Related]

  • 16. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G, Campana S, Festini F, Mascherini M, Döring G.
    Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
    [Abstract] [Full Text] [Related]

  • 17. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F, Brockhaus F, Angyalosi G.
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [Abstract] [Full Text] [Related]

  • 18. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE, Mastoridis P.
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [Abstract] [Full Text] [Related]

  • 19. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.
    Song Z, Wu H, Mygind P, Raventos D, Sonksen C, Kristensen HH, Høiby N.
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3868-74. PubMed ID: 16127064
    [Abstract] [Full Text] [Related]

  • 20. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS, Egan M, Kazmierczak BI.
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.